Age-related macular degeneration (AMD) stands as a leading cause of vision loss among the elderly population in developed countries. This progressive eye disease affects the macula, the central part of the retina responsible for sharp, central vision. As the global population ages, the prevalence of AMD is projected to rise significantly, creating a massive and growing public health challenge. The disease's impact is not limited to vision loss; it also profoundly affects a patient's quality of life, leading to a loss of independence and an increased risk of depression. The market for AMD treatments is thus driven by an urgent and expanding need for effective therapies that can halt disease progression and preserve vision. While a significant portion of the market is focused on managing the more severe "wet" form of the disease, a major unmet need remains for effective treatments for "dry" AMD, which accounts for the vast majority of cases. This has fueled intense research and development, with pharmaceutical and biotechnology companies pouring resources into finding new and innovative solutions. The market's growth is a direct reflection of this global health crisis and the concerted efforts to combat it. For a comprehensive overview of the current landscape and future trends, you can refer to the detailed Age-Related Macular Degeneration Market report.